Full Press Release Details
argenx announces results of Annual General Meeting
May 7, 2024 - 5:30pm ET
Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives
of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today.
All items on the agenda received a majority of
votes in favor except for agenda item 5 (adoption of the remuneration policy).
As part of the approved resolutions:
and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic
researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio
of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker
in the U.S., the EU and UK, and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several
earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com/
For further information, please contact: